US 11,905,535 B2
Genetic engineering of fungi to modulate tryptamine expression
Thomas Henley, New York, NY (US); Modassir Choudhry, New York, NY (US); and Jose Fernandez-Gomez, New York, NY (US)
Assigned to Empyrean Nueroscience, Inc., New York, NY (US)
Filed by EMPYREAN NEUROSCIENCE, INC., New York, NY (US)
Filed on Jul. 15, 2022, as Appl. No. 17/812,826.
Application 17/812,826 is a continuation of application No. 17/711,270, filed on Apr. 1, 2022.
Application 17/711,270 is a continuation of application No. PCT/US2020/053842, filed on Oct. 1, 2020.
Claims priority of provisional application 62/909,159, filed on Oct. 1, 2019.
Prior Publication US 2022/0396780 A1, Dec. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/02 (2006.01); A61K 36/07 (2006.01); C12N 9/10 (2006.01); C12N 9/12 (2006.01); C12N 9/88 (2006.01)
CPC C12N 9/0083 (2013.01) [A61K 36/07 (2013.01); C12N 9/1007 (2013.01); C12N 9/1205 (2013.01); C12N 9/88 (2013.01); C12Y 114/99 (2013.01); C12Y 201/01 (2013.01); C12Y 207/01 (2013.01); C12Y 401/01 (2013.01)] 19 Claims
 
1. A genetically modified Basidiomycota fungus, comprising an expressed exogenous PsiD gene or an expressed exogenous PsiH gene, or both, and wherein the genetically modified Basidiomycota fungus produces an increased production of a compound selected from the group consisting of:

OG Complex Work Unit Chemistry
and any combination thereof, as compared to production of the same compound(s) in a comparable control Basidiomycota fungus without the expressed exogenous PsiD gene or the expressed exogenous PsiH gene, or both, and wherein
the genetically modified Basidiomycota fungus comprises at least 200% more psilocybin measured by dry weight of the genetically modified Basidiomycota fungus compared to an amount of psilocybin in a comparable control Basidiomycota fungus without the expressed exogenous PsiD gene or the expressed exogenous PsiH gene, or both.